Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"

Clicks: 374
ID: 106942
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 55 articles by views in pharmacological research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
ceccarelli2020letterpharmacological Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ceccarelli, Gabriele;Nardi, Katiuscia;Marchesani, Francesca;
Journal pharmacological research
Year 2020
DOI
S1043-6618(20)31241-X
URL
Keywords
traditional chinese medicine rutin (pubchem cid: 5280805) network pharmacology action mechanism quercetin (pubchem cid: 5280343) kaempferol (pubchem cid: 5280863) covid-19 sars-cov-2 ace2 3cl pro baicalein (pubchem cid: 5281605) isorhamnetin (pubchem cid: 5281654) luteolin (pubchem cid: 5280445) naringenin (pubchem cid: 932) ursolic acid (pubchem cid: 64945) wogonin (pubchem cid: 5281703) β-sitosterol (pubchem cid: 222284)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.